Project Grant R01CA300057
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $486K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbia, MO 65211, USA
Similar Awards
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion targeted for August 31, 2030. The award supports fundamental research to identify and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs) as a therapeutic target for acute myeloid leukemia (AML) patients. The research...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $954,436 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 23, 2025, with a completion date of July 31, 2030. This award funds fundamental research investigating the persistence of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) patients during tyrosine kinase inhibitor (TKI) treatment, with...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Grant Award Summary Baylor College of Medicine received a $2.4 million Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 15, 2025 through July 31, 2029. The award funds research investigating the role of RNA sequestration in acute myeloid leukemia (AML), specifically examining how the RNA helicase DDX6 (DEAD-Box Helicase 6) regulates post-transcriptional processes critical to leukemia development and...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The research project investigates dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining BCL-2 (B-cell lymphoma-2) inhibition with CD123-directed natural killer (NK) cell engager immunotherapies. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $217,600 Project Grant to New York University School of Medicine under the Cancer Research Manpower program (CFDA 93.398) on September 26, 2025, with a completion date of March 31, 2029. This award supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The research project focuses on understanding T cell acute lymphoblastic...
- Federal Grant Award Summary The National Cancer Institute awarded a $646,881 Project Grant to the Regents of the University of Michigan (Office of Research and Sponsored Projects) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2031. This research project focuses on developing and evaluating small molecule inhibitors targeting ASH1L (Absent, Small or Homeotic 1-Like), a histone methyltransferase protein implicated in acute leukemia...
- Federal Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $484,405 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2030. The award funds fundamental research investigating how NSD2 (nuclear receptor binding SET domain protein 2) mutations drive acute lymphoblastic leukemia (ALL) transformation, with particular focus on relapsed B-cell ALL...